Arsani William - 09 Aug 2024 Form 4 Insider Report for Design Therapeutics, Inc. (DSGN)

Role
Director
Signature
/s/ Mustapha Parekh, Attorney-in-Fact
Issuer symbol
DSGN
Transactions as of
09 Aug 2024
Net transactions value
-$3,463,214
Form type
4
Filing time
12 Aug 2024, 16:30:21 UTC
Previous filing
17 Jun 2024
Next filing
12 Jun 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DSGN Common Stock Sale $3,463,214 -814,874 -100% $4.25 0 09 Aug 2024 By Logos SPV I LP F1
holding DSGN Common Stock 1,217,627 09 Aug 2024 By Logos Opportunities Fund II, L.P. F1
holding DSGN Common Stock 3,000,000 09 Aug 2024 By Logos Global Master Fund LP F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Logos Global Management LP is the investment advisor of private funds, including Logos Opportunities Fund II LP ("LOF II") and Logos SPV 1 LP ("SPV 1"). Logos Opportunities GP LLC ("GP I") is the general partner of LOF II. Logos Opportunities II GP LLC ("GP II") is the general partner of SPV 1. The Reporting Person is the Managing Member of both GP I and GP II. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F2 Logos GP LLC ("Fund GP") is the general partner of Logos Global Master Fund LP (the "Fund"). The Reporting Person is the Managing Member of Fund GP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.